Show Me The Money: Contineum Therapeutics' Turnaround From Lows To New Highs

Contineum Therapeutics, Inc. (CTNM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES SAN DIEGO – July 30, 2026 – Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering

AMD unveiled two AI-focused hardware platforms at IFA 2026: the Ryzen AI Max Pro 400 (Kraken Halo) and the Threadripper Halo Station. The former, with unified memory, can run 300-billion-parameter AI models locally. The latter, a liquid-cooled workstation, supports over 1-trillion-parameter models. AMD claims local AI reduces costs versus cloud-based solutions, citing industry data on token usage and pricing.

SoFi Technologies and Kraken's parent company, Payward, have partnered to connect their products. Kraken's institutional clients will use SoFi's dollar settlement network, and SoFi will use Kraken Prime for digital asset liquidity. SoFi's stablecoin, SoFiUSD, will be added to Kraken's platforms. According to experts, this partnership reflects the growing integration of digital assets into traditional banking.

Ocugen, Inc. (OCGN) shares fell slightly as the company announced the first patient was dosed in a global Phase 3 trial for OCU410, a gene therapy candidate for dry age-related macular degeneration. The FDA granted OCU410 RMAT designation, potentially accelerating development. Ocugen aims to offer a one-time treatment for the condition, with no approved treatments outside the U.S. and limited options in the U.S.

Studsvik AB, a Swedish nuclear services company, agreed with GE Vernova Hitachi (GVH) and Samsung C&T to build 1.2 GW of nuclear energy using the BWRX-300 reactor design. The project, targeting operation in the mid-2030s, will be developed at one of two sites. Studsvik, with a market cap under $200M and 2025 revenue under $100M, acquired Kärnfull Next earlier this year, entering reactor development. This follows GE Vernova's loss to Rolls-Royce in a prior Swedish nuclear project.

AstraZeneca and Amgen reported positive phase 3 trial results for tezepelumab (Tezspire) in treating eosinophilic esophagitis (EoE). The study showed improved dysphagia and histologic remission at weeks 24 and 52 compared to placebo. The companies plan to share data with regulators. Tezspire is already FDA-approved for severe asthma and chronic rhinosinusitis.